Prime Medicine Common Etf Net Income
| PRME Etf | USD 3.29 0.02 0.60% |
As of the 18th of February 2026, Prime Medicine holds the Variance of 29.59, risk adjusted performance of (0.01), and Coefficient Of Variation of (4,783). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Prime Medicine, as well as the relationship between them. Please check Prime Medicine Common standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if Prime Medicine Common is priced some-what accurately, providing market reflects its current price of 3.29 per share.
Prime Medicine's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Prime Medicine's valuation are provided below:Gross Profit -154.1 M | Market Capitalization 595.7 M | Enterprise Value Revenue 84.3472 | Revenue | Earnings Share (1.41) |
Prime Medicine Common's market price often diverges from its book value, the accounting figure shown on Prime's balance sheet. Smart investors calculate Prime Medicine's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Prime Medicine's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Prime Medicine's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Prime Medicine should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Prime Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Prime Medicine 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Prime Medicine's etf what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Prime Medicine.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in Prime Medicine on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding Prime Medicine Common or generate 0.0% return on investment in Prime Medicine over 90 days. Prime Medicine is related to or competes with Maravai Lifesciences, Kura Oncology, Bicara Therapeutics, Vir Biotechnology, Replimune, Septerna Common, and Tyra Biosciences. Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing ... More
Prime Medicine Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Prime Medicine's etf current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Prime Medicine Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 25.37 | |||
| Value At Risk | (8.19) | |||
| Potential Upside | 10.19 |
Prime Medicine Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prime Medicine's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Prime Medicine's standard deviation. In reality, there are many statistical measures that can use Prime Medicine historical prices to predict the future Prime Medicine's volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | (0.09) |
Prime Medicine February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.08) | |||
| Mean Deviation | 4.05 | |||
| Coefficient Of Variation | (4,783) | |||
| Standard Deviation | 5.44 | |||
| Variance | 29.59 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | (0.09) | |||
| Maximum Drawdown | 25.37 | |||
| Value At Risk | (8.19) | |||
| Potential Upside | 10.19 | |||
| Skewness | 0.8359 | |||
| Kurtosis | 0.937 |
Prime Medicine Common Backtested Returns
Prime Medicine Common maintains Sharpe Ratio (i.e., Efficiency) of -0.0104, which implies the entity had a -0.0104 % return per unit of risk over the last 3 months. Prime Medicine Common exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Prime Medicine's Coefficient Of Variation of (4,783), variance of 29.59, and Risk Adjusted Performance of (0.01) to confirm the risk estimate we provide. The etf holds a Beta of 1.39, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Prime Medicine will likely underperform.
Auto-correlation | 0.62 |
Good predictability
Prime Medicine Common has good predictability. Overlapping area represents the amount of predictability between Prime Medicine time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Prime Medicine Common price movement. The serial correlation of 0.62 indicates that roughly 62.0% of current Prime Medicine price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.62 | |
| Spearman Rank Test | 0.31 | |
| Residual Average | 0.0 | |
| Price Variance | 0.13 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Prime Medicine Common reported net income of (195.88 Million). This is much lower than that of the Biotechnology family and significantly lower than that of the Health Care category. The net income for all United States etfs is notably higher than that of the company.
Prime Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prime Medicine's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Prime Medicine could also be used in its relative valuation, which is a method of valuing Prime Medicine by comparing valuation metrics of similar companies.Prime Medicine is currently under evaluation in net income as compared to similar ETFs.
Prime Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Prime Medicine's current stock value. Our valuation model uses many indicators to compare Prime Medicine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Prime Medicine competition to find correlations between indicators driving Prime Medicine's intrinsic value. More Info.Prime Medicine Common is rated number one ETF in price to earning as compared to similar ETFs. It is regarded fourth largest ETF in price to book as compared to similar ETFs fabricating about 0.26 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Prime Medicine Common is roughly 3.89 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Prime Medicine by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Prime Medicine Institutional Holders
Institutional Holdings refers to the ownership stake in Prime Medicine that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Prime Medicine's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Prime Medicine's value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 1.5 M | State Street Corp | 2025-06-30 | 1.2 M | Greenwich Wealth Management Llc | 2025-06-30 | 846.2 K | Schonfeld Strategic Advisors Llc | 2025-06-30 | 818.5 K | Farallon Capital Management, L.l.c. | 2025-06-30 | 750 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 587.7 K | Citadel Advisors Llc | 2025-06-30 | 521.5 K | Charles Schwab Investment Management Inc | 2025-06-30 | 518.6 K | Northern Trust Corp | 2025-06-30 | 512.2 K | Alphabet Inc | 2025-06-30 | 15.1 M | T. Rowe Price Investment Management,inc. | 2025-06-30 | 6.5 M |
Fund Asset Allocation for Prime Medicine
The fund invests 99.55% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides Prime Medicine's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors for a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will manage securities in the fund's portfolio as market conditions and the fund's objectives change.
Prime Fundamentals
| Return On Equity | -1.12 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (44.06) % | ||||
| Current Valuation | 504.14 M | ||||
| Shares Outstanding | 180.51 M | ||||
| Shares Owned By Insiders | 17.62 % | ||||
| Shares Owned By Institutions | 68.73 % | ||||
| Number Of Shares Shorted | 27.08 M | ||||
| Price To Earning | 14.40 X | ||||
| Price To Book | 3.70 X | ||||
| Price To Sales | 99.66 X | ||||
| Revenue | 2.98 M | ||||
| Gross Profit | (154.05 M) | ||||
| EBITDA | (196.34 M) | ||||
| Net Income | (195.88 M) | ||||
| Cash And Equivalents | 146.66 M | ||||
| Cash Per Share | 6.39 X | ||||
| Total Debt | 40.79 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 6.70 X | ||||
| Book Value Per Share | 0.92 X | ||||
| Cash Flow From Operations | (122.86 M) | ||||
| Short Ratio | 8.22 X | ||||
| Earnings Per Share | (1.41) X | ||||
| Target Price | 6.46 | ||||
| Number Of Employees | 214 | ||||
| Beta | 2.72 | ||||
| Market Capitalization | 595.69 M | ||||
| Total Asset | 297.51 M | ||||
| Retained Earnings | (687.21 M) | ||||
| Working Capital | 173.93 M | ||||
| One Year Return | (0.31) % | ||||
| Three Year Return | 3.82 % | ||||
| Net Asset | 297.51 M | ||||
| Equity Positions Weight | 99.55 % |
About Prime Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prime Medicine Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prime Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prime Medicine Common based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Prime Etf
Prime Medicine financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine security.